Cyclooxygenase-2 inhibitors and cardiovascular risk.
Smith
Eldon R
ER
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001315:Australia; D002170:Canada; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000453:epidemiology; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry; D004348:Drug Labeling; D006801:Humans; D015994:Incidence; D007783:Lactones / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D011720:Pyrazoles / Q000009:adverse effects; D012307:Risk Factors; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib